IMPACT THAT MATTERS

Driving
CMT Research
with the
Patient’s Voice

With your help support love
nothing is impossible!

Drive Research

Drive Research

Turn your symptoms into science

Join Team CMT

Join Team CMT

Join the movement to make a difference for those living with CMT

Pledge Monthly

Pledge Monthly

Start your Monthly Gift of $10 today or consider the many other ways to give!

Research CMT

Research CMT

HNF has been conducting patient-focused research dating back to 2007.

Gift a Birthday

Gift a Birthday

Celebrate your birthday with a purpose! Start a Birthday CMT Fundraiser.

Allison and Daniel Cohen

Welcome To The
Hereditary Neuropathy Foundation

Our mission is to increase awareness and accurate diagnosis of Charcot-Marie-Tooth (CMT) and related inherited neuropathies, support people living with CMT and their families with critical information to improve quality of life, and fund research that will lead to treatments and cures.

What is CMT?

Genetic Testing

Patient Resources

Pediatrics & CMT

Newsletter

Join for notifications on events, campaigns, & news

About HNF

Founded in the early 2000’s, HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD) as a collaborative effort with academia, government, and industry to develop treatments for CMT.

In accordance with the FDA’s patient-focused drug development guidance for enhancing the incorporation of the patient’s voice in medical product development and regulatory decision making, HNF has developed a regulatory strategy to support FDA Guidelines to engage with industry early on and assist with collecting and submitting robust and meaningful patient experience data, and other relevant information from patients and caregivers, such as identifying what is important to patients.

HNF is actively committed to increasing awareness and accurate diagnosis of CMT and providing patients and families with critical information to improve quality of life.

mtrfr-c12orf65

From Our Blog

LATEST

Breaking News for SORD Deficiency Patients

Breaking News for SORD Deficiency Patients

The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.

HNF Contributes CMTRN Data to C-Path’s RDCA-DAP

HNF Contributes CMTRN Data to C-Path’s RDCA-DAP

HNF Contributes CMTRN Data to C-Path’s RDCA-DAP, Strengthening Research Capabilities for Inherited Neuropathies Integration of CMTRN data into RDCA-DAP promises new insights into Charcot-Marie-Tooth disease and related neuropathies, fueling advancements in treatment...

New CMT gene discovery, CRYAB

New CMT gene discovery, CRYAB

Do you have late onset autosomal dominant CMT2 – subtype unknown, with breathing involvement, unexplained cardiac complications, and/or congenital cataracts?

Featured

HNF Contributes CMTRN Data to C-Path’s RDCA-DAP

HNF Contributes CMTRN Data to C-Path’s RDCA-DAP

HNF Contributes CMTRN Data to C-Path’s RDCA-DAP, Strengthening Research Capabilities for Inherited Neuropathies Integration of CMTRN data into RDCA-DAP promises new insights into Charcot-Marie-Tooth disease and related neuropathies, fueling advancements in treatment...

Featured Webinars

Active Hands

Active Hands

Hear from Rob Smith, Inventor and Director of Active Hands and learn about these life-impacting products designed especially for people living with reduced hand function.

CMT-Connect Pain Webinar

CMT-Connect Pain Webinar

New CMT-Connect Webinar Pain Series will focus on a particular type of pain, its common causes, available treatments and future treatments on the horizon.

UPCOMING EVENTS

TRENDING